RenovoRx Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	5.03	5.73	5.65	2.63	0.82	0.9
Research & Development	5.59	5.67	4.3	3.04	2.39	3
Operating Expenses	10.61	11.4	9.95	5.67	3.2	3.9
Operating Income	-10.61	-11.4	-9.95	-5.67	-3.2	-3.9
Interest Expense / Income	0.11	0.11	0.06	0.83	0.59	-0.06
Other Expense / Income	-2.67	-1.27	-0.12	-0.18	0.01	0.01
Pretax Income	-8.05	-10.23	-9.89	-6.32	-3.8	-3.84
Net Income	-8.05	-10.23	-9.89	-6.32	-3.8	-3.84
Shares Outstanding (Basic)	15	10	9	5	2	2
Shares Outstanding (Diluted)	15	10	9	5	2	2
Shares Change	64.44%	13.69%	73.50%	135.64%	1.70%	-
EPS (Basic)	-0.72	-0.99	-1.09	-1.21	-1.72	-1.76
EPS (Diluted)	-0.72	-0.99	-1.09	-1.21	-1.72	-1.76
Free Cash Flow	-9.76	-10.26	-8.81	-5.93	-3.53	-3.35
Free Cash Flow Per Share	-0.65	-1.00	-0.97	-1.14	-1.59	-1.54
EBITDA	-7.94	-10.12	-9.83	-5.48	-3.21	-3.9
Depreciation & Amortization	0	0	0.01	0.01	0	0
EBIT	-7.94	-10.12	-9.83	-5.49	-3.21	-3.9

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).